Proposed changes to the Common Drug Review (CDR) process have been published for consultation purposes. According to the CDR, the changes are intended "to facilitate earlier access to drugs without compromising the high quality of CDR reviews." The deadline for comments is January 21, 2009.
One change would allow manufacturers to make resubmissions at a lower list price if the Canadian Expert Drug Advisory Committee (CEDAC) has indicated that a lower price would cause it to change a negative recommendation to a positive one. A second change would allow manufacturers to make submissions to CDR during the pre-NOC period. This procedure would be intended to lower the delay between marketing approval by Health Canada and the ultimate listing recommendation by CDR.
For a report on the proposed changes, please see: http://www.gowlings.com/resources/enewsletters/DrugPricingReimbursement/ Htmfiles/V2N15_20081211.en.html